U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
Bay Area-based genomics company 10X Genomics has become one of the fastest growing privately held companies in the region with an earnings increase of more than 2,000 percent over a three-year period. As a result of that growth, the company optioned space in its town of Pleasanton, Calif.
German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.
Regeneron plans to invest more than $800 million over seven years to expand the company’s facilities in Rensselaer County, New York. This expansion is expected to create 1,500 new full-time jobs.
Boehringer Ingelheim announced a 230 million euro investment into a new biologicals development center at the company’s research and development site in Biberach, Germany.
Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.
Backed by financing from a collaboration with Novartis and an $83 million financing round, Homology Medicines is moving to a new facility with more than triple the space of its headquarters.
The U.S. Food and Drug Administration issued a warning letter to Fresenius Kabi AG of Germany for its plant in India.